Login / Signup

Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-κB expressions

Fatih OltuluAylin BuhurÇevik GürelGökçe Cerren KuşçuMelih DagdevirenNefise Ülkü Karabay YavaşoğluTimur KoseAltug Yavasoglu
Published in: Turkish journal of medical sciences (2019)
This study indicated that mid-dose losartan administration may have a therapeutic effect by inhibiting apoptosis and regulating iNOS, eNOS, VEGF, and NF-κB protein expressions in DM-induced hepatic damage.
Keyphrases